Daily non-political popular news in brief.

New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis

The innovative new rheumatoid arthritis drug Actemra has been shown to significantly improve the signs and symptoms of rheumatoid arthritis in patients who failed to achieve an adequate response to traditional disease modifying agents. Exciting new data from the TOWARD1 study, being presented as a late breaker, at the American College of Rheumatology Annual Scientific Meeting in Boston, Nov. 6-11, reinforce the benefit of tackling RA through the inhibition of the IL-6 pathway.

Read more »

Keywords: actemra, data, shows, significant, benefit, patients, suffering, rheumatoid, arthritis, show, patient, arthriti

« Previous | Next »

Similar news on "New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis":

1. Latest data shows MabThera provides significant, sustained relief from symptoms of RA
   06-13-2007 · EurekAlert!
   New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
   Similar news · Read more »
   
2. Annals of Internal Medicine tip sheet for March 20, 2007
   03-19-2007 · EurekAlert!
   The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
   Similar news · Read more »
   
3. New study reveals gender disparity in anti-TNF treatment for rheumatoid arthritis
   06-14-2007 · EurekAlert!
   Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis. Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs -- very effective but expensive modern medications against this disease -- at a higher perceived level of disease activity, and when they are reporting more severe pain than their male counterparts.
   Similar news · Read more »
   
4. First prospective study shows improvement of rheumatoid arthritis during pregnancy
   06-14-2007 · EurekAlert!
   Disease activity in patients with rheumatoid arthritis is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, RA improved significantly from the first trimester to the third trimester of the participants' pregnancy and this effect extended into the postpartum stage.
   Similar news · Read more »
   
5. Mapping rheumatoid arthritis -- first multinational review of RA shows
   06-14-2007 · EurekAlert!
   In the first international "map of rheumatoid arthritis," spanning Europe and beyond, significant national differences in RA severity can be directly traced to national economics, most notably health expenditure, as exposed today by data from the QUEST-RA Study presented at EULAR 2007, the Annual Congress of the European League Against Rheumatism, Barcelona, Spain.
   Similar news · Read more »
   
6. Obesity adds to the quality of life burden of rheumatoid arthritis
   06-14-2007 · EurekAlert!
   The global obesity epidemic was issued with a further health warning today -- that obesity exacerbates the quality of life of patients with rheumatoid arthritis. New data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, shows that RA in obese patients is associated with worse quality of life outcomes on four key levels: pain, fatigue, physical function and overall utility scores.
   Similar news · Read more »
   
7. Phase 3 data show golimumab improved psoriatic arthritis symptoms
   11-07-2007 · EurekAlert!
   Patients with active psoriatic arthritis receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase 3 biologic study ever completed in subjects with psoriatic arthritis.
   Similar news · Read more »
   
8. Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
   11-13-2006 · EurekAlert!
   Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
   Similar news · Read more »
   
9. Longer term breast feeding protects mother from risk of developing rheumatoid arthritis
   06-15-2007 · EurekAlert!
   Breast feeding for a period of 13 months or more has been shown to reduce the mother's the risk of developing rheumatoid arthritis, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, the longer the breast feeding period, the lower the mother's risk of developing RA in later life. Comparable use of oral contraceptives or hormone replacement therapy did not show a significant effect on the risk of developing RA.
   Similar news · Read more »
   
10. Disability from long-term rheumatoid arthritis reduced with biologic treatment
    06-12-2007 · EurekAlert!
    New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
    Similar news · Read more »